Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenge's faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design.
Vaccine trial reveals chinks in HIV's armour doi:10.1038/nature.2012.11380 Analysis identifies target for immune response that could improve AIDS vaccines. Full Text
Patient power doi:10.1038/nbt.2360 Patient foundations are not only exploring new funding models but also catalyzing translational research, with notable successes. Full Text
An Audience with Mark McClellan doi:10.1038/nrd3837 Mark McClellan, Director of the Brookings Institution's health care reform centre, discusses the need for better metrics to measure the health of biomedical innovation. Full Text
Lack of BRCA testing approval creates snag for cancer trials doi:10.1038/nm0912-1310a Recent court rulings about the intellectual property of certain parts of the cancer-associated BRCA genes could have far-reaching repercussions for clinical trials and drug development. Full Text
New home for bromodomains doi:10.1038/scibx.2012.914 Tensha's bromodomain inhibitors could prevent sperm production and be developed as a male contraceptive. The biotech has exclusive rights to the findings. Full Text
The pharmaceutical market for obesity therapies doi:10.1038/nrd3730 In the wake of the recent approvals of the first new obesity therapies in more than a decade, Wong and colleagues analyse their market prospects as well as the late-stage pipeline. Full Text
Cancer: Passenger deletions create cancer-specific Achilles heel doi:10.1038/nrd3826 Cancer cells tend to shed tumour suppressor genes — and often delete neighbouring genes in the process. New research shows that genes deleted in cells that neighbour cancer cells create cancer cell-specific vulnerabilities that can be targeted by new anticancer strategies. Full Text
Structure-based drug design: Opening the door to an epigenetic target doi:10.1038/nrd3827 A structure-guided approach has been used to identify the first specific small-molecule inhibitor of a jumonji histone demethylase. Full Text
Ischaemic disorders: Nanotherapeutic delivers clot-busting drug doi:10.1038/nrd3828 Shear-activated nanotherapeutics can deliver thrombolytic drugs to the site of vascular occlusion, enabling rapid clot dissolution and an increase in survival in mouse models. Full Text
Autophagy modulation as a potential therapeutic target for diverse diseases doi:10.1038/nrd3802 This article provides an overview of the mechanisms and regulation of autophagy, the role of this pathway in disease and strategies for therapeutic modulation. Full Text
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons doi:10.1038/nrd3739 Emerging knowledge on the role of the hypothalamus may facilitate the discovery of new agents that are more effective than current anti-obesity drugs, and have an acceptable benefit–risk profile. Full Text
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis doi:10.1038/nchembio.1060 A small-molecule activator specific for PKM2 binds to a site distinct from the endogenous activator fructose-1,6-bisphosphate, promoting tetramerization and constitutive activation of PKM2, to inhibit xenograft tumor growth in mice. Full Text
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans doi:10.1038/nm.2901 Genetic or pharmacological inhibition of Epha4 is protective in rodent and zebrafish models of amyotrophic lateral sclerosis. In two patients, mutations in Epha4 are associated with longer survival, suggesting Epha4 may be targeted therapeutically. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment